Commentary questions long-term bone and reproductive effects of GLP-1 drugs in adolescents

A commentary published in the Journal of Pediatric and Adolescent Gynecology argues that the long-term effects of GLP-1 receptor agonists on adolescents' bones, reproductive health and eating behavior remain uncertain, at a time when the drugs are prescribed more often to teenagers for obesity and type 2 diabetes ^[1][2].

The article is a review of existing evidence, not a new trial. It focuses on a drug class that includes semaglutide (Ozempic, Wegovy, Rybelsus) and liraglutide, and it notes growing interest in extending adolescent use to polyendocrine metabolic ovarian syndrome, or PMOS, formerly called polycystic ovary syndrome ^[2].

The authors write that adolescence is the critical window for peak bone mass acquisition, and that rapid weight loss from medication "may theoretically impair bone mineral accrual" ^[2]. Adult evidence cited in the commentary suggests modest reductions in bone mineral density tied to weight loss, while structured exercise may soften those effects ^[2]. For adolescents, the commentary says no long-term skeletal data exist ^[2].

On what has been measured: adult studies show improvements in weight loss, insulin resistance and menstrual regularity with GLP-1 receptor agonist therapy, according to the commentary ^[2]. In adolescents with obesity, clinical trials of liraglutide and semaglutide showed significant weight reduction with no short-term effects on growth or pubertal development ^[2]. The commentary does not report trial sizes, follow-up periods or the size of the weight reductions.

Reproductive questions are also open. GLP-1 receptor agonists are not recommended during pregnancy, and no data exist on reproductive outcomes following adolescent exposure, the authors write ^[2].

Another concern is eating disorders. The commentary says the drugs' potent appetite-suppressing effects raise concerns about misuse or about worsening eating disorders in adolescents, a group the authors describe as uniquely vulnerable to body image pressure ^[2]. How often such misuse occurs in adolescents is not quantified in the article.

The authors conclude that GLP-1 receptor agonists are a promising adjunct therapy for adolescents with obesity, type 2 diabetes and PMOS, but that long-term skeletal, reproductive, psychological and endocrine outcomes remain uncertain ^[2]. They write that careful patient selection, bone health monitoring, resistance exercise, contraceptive counseling and screening for disordered eating may be essential when the drugs are considered for adolescents — guidance aimed at clinicians rather than instructions for patients ^[2]. The authors declare no competing financial interests ^[2].

Why it matters for patients

For families weighing GLP-1 treatment for a teenager, the practical point is that the evidence base covers short-term weight and metabolic results, not the decades in which bone density and reproductive health are established ^[2]. Bone mass peaks during adolescence and young adulthood, and the commentary says the effect of medication-driven weight loss during that window has not been measured in adolescents ^[2].

The commentary also raises the possibility that appetite suppression could be misused or could worsen disordered eating in teenagers, and states that how common that is has not been established ^[2]. Nothing in the article changes current prescribing rules or product labels, and it does not recommend against using the drugs in adolescents; it calls for monitoring and screening alongside treatment ^[2].

What remains unknown, according to the commentary: whether adolescent exposure affects peak bone mass, menstrual or fertility outcomes later in life, and how often disordered eating or misuse occurs in this age group ^[2]. No timelines for new studies or regulatory action are included in the article ^[1][2].